Zinc monocysteine

Drug Profile

Zinc monocysteine

Alternative Names: AEN-100; AEN-100/AEN-200; reaZin; Zinc cysteine - Adeona

Latest Information Update: 21 Sep 2015

Price : $50

At a glance

  • Originator Adeona Pharmaceuticals
  • Developer Synthetic Biologics
  • Class Antidementias; Cysteines; Zinc compounds
  • Mechanism of Action Antioxidants; Free radical scavengers; Glutathione peroxidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Amyotrophic lateral sclerosis

Most Recent Events

  • 16 Feb 2012 Adeona Pharmaceuticals is now called Synthetic Biologics
  • 30 Nov 2011 Efficacy and adverse events data from a phase I/II trial in Amyotrophic lateral sclerosis released by Adeona (ADNM)
  • 30 Sep 2011 Preclinical trials in Amyotrophic lateral sclerosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top